CBOZANTINIB FOR OTHER THAN MEDULLARY THRYOID CANCER -PRO
This drug is indicated for for the treatment of patients with advanced renal cell carcinoma (RCC). In 2012 cabozantinib in its capsule formulation was approved by the U.S. FDA under the name Cometriq for treating patients with medullary thyroid cancer. However, the thyroid cancer in this case is not medullary.
There is some support for using it in other types of thyroid cancer. Cabozantinib (Cometriq) has demonstrated significant activity in the first-line setting for radioiodine-refractory differentiated thyroid carcinoma, according to data from a single-site phase II trial presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium.
Brose MS, Shenoy S, Bhat N, et al: A phase II trial of cabozantinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma in the first-line setting. 2018 Multidisciplinary Head and Neck Cancers Symposium. Abstract 8. Presented February 16, 2018.
2. Cabanillas ME, Brose MS, Holland J, et al: A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid 24:1508-1514, 2014.